Fallopian Tube Cancer - Pipeline Review, H1 2018

  • ID: 4521336
  • Drug Pipelines
  • 950 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • Fate Therapeutics Inc
  • Johnson & Johnson
  • Oasmia Pharmaceutical AB
  • PTC Therapeutics Inc
  • MORE
Fallopian Tube Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2018, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients.

Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights:

This latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 13, 61, 41, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 7 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • Fate Therapeutics Inc
  • Johnson & Johnson
  • Oasmia Pharmaceutical AB
  • PTC Therapeutics Inc
  • MORE
Introduction

Fallopian Tube Cancer - Overview

Fallopian Tube Cancer - Therapeutics Development

Fallopian Tube Cancer - Therapeutics Assessment

Fallopian Tube Cancer - Companies Involved in Therapeutics Development

Fallopian Tube Cancer - Drug Profiles

Fallopian Tube Cancer - Dormant Projects

Fallopian Tube Cancer - Discontinued Products

Fallopian Tube Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Fallopian Tube Cancer - Pipeline by AbbVie Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Fallopian Tube Cancer - Pipeline by Altor BioScience Corp, H1 2018

Fallopian Tube Cancer - Pipeline by Amgen Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Fallopian Tube Cancer - Pipeline by Astellas Pharma Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H1 2018

Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Bayer AG, H1 2018

Fallopian Tube Cancer - Pipeline by BeiGene Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Fallopian Tube Cancer - Pipeline by Boston Biomedical Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Fallopian Tube Cancer - Pipeline by Caladrius Biosciences Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Celgene Corp, H1 2018

Fallopian Tube Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Celsion Corp, H1 2018

Fallopian Tube Cancer - Pipeline by Celyad SA, H1 2018

Fallopian Tube Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by Eisai Co Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by Eli Lilly and Co, H1 2018

Fallopian Tube Cancer - Pipeline by EpiThany Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Exelixis Inc, H1 2018

Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by Fate Therapeutics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by Genentech Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Genor BioPharma Co Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018

Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H1 2018

Fallopian Tube Cancer - Pipeline by Gradalis Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Ignyta Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Immune Design Corp, H1 2018

Fallopian Tube Cancer - Pipeline by ImmunoGen Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Immunovaccine Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Innate Pharma SA, H1 2018

Fallopian Tube Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H1 2018

Fallopian Tube Cancer - Pipeline by Juno Therapeutics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Kazia Therapeutics Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H1 2018

Fallopian Tube Cancer - Pipeline by MedImmune LLC, H1 2018

Fallopian Tube Cancer - Pipeline by Merck & Co Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Merck KGaA, H1 2018

Fallopian Tube Cancer - Pipeline by Mersana Therapeutics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Fallopian Tube Cancer - Pipeline by MolMed SpA, H1 2018

Fallopian Tube Cancer - Pipeline by Mycenax Biotech Inc, H1 2018

Fallopian Tube Cancer - Pipeline by NewLink Genetics Corp, H1 2018

Fallopian Tube Cancer - Pipeline by Novartis AG, H1 2018

Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2018

Fallopian Tube Cancer - Pipeline by OBI Pharma Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Omnitura Therapeutics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Oncobiologics Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Oncolix Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc, H1 2018

Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Fallopian Tube Cancer - Pipeline by Pfizer Inc, H1 2018

Fallopian Tube Cancer - Pipeline by Pharma Mar SA, H1 2018

List of Figures

Number of Products under Development for Fallopian Tube Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Adaptimmune Therapeutics Plc
  • Advenchen Laboratories LLC
  • Altor BioScience Corp
  • Amgen Inc
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Bayer AG
  • BeiGene Ltd
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Caladrius Biosciences Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Celsion Corp
  • Celyad SA
  • Cotinga Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EpiThany Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Genor BioPharma Co Ltd
  • GlaxoSmithKline Plc
  • Glycotope GmbH
  • Gradalis Inc
  • Ignyta Inc
  • Immune Design Corp
  • ImmunoGen Inc
  • Immunovaccine Inc
  • Innate Pharma SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • MabVax Therapeutics Holdings Inc
  • Madrigal Pharmaceuticals Inc.
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Mersana Therapeutics Inc
  • Millennium Pharmaceuticals Inc
  • MolMed SpA
  • Mycenax Biotech Inc
  • NewLink Genetics Corp
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OBI Pharma Inc
  • Omnitura Therapeutics Inc
  • Oncobiologics Inc
  • Oncolix Inc
  • Oncolytics Biotech Inc
  • OncoMed Pharmaceuticals Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Plexxikon Inc
  • PsiOxus Therapeutics Ltd
  • PTC Therapeutics Inc
  • Richter Gedeon Nyrt
  • Rigel Pharmaceuticals Inc
  • Samyang Holdings Corp
  • Sanofi
  • Sanofi Pasteur SA
  • SELLAS Life Sciences Group Inc
  • Sotio AS
  • Sun Pharma Advanced Research Company Ltd
  • Syndax Pharmaceuticals Inc
  • TapImmune Inc
  • Tesaro Inc
  • Tyrogenex Inc
  • Vascular Biogenics Ltd
  • Verastem Inc
  • Vyriad Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll